The global gene therapy market is estimated to grow from $2.4 billion in 2024 to $16.5 billion by 2035, representing a CAGR of 19.25% during the forecast period till 2035.
This has essentially led to the foundation of novel class of therapeutics known as gene therapies. According to the USFDA, gene therapy is defined as a the method introducing genetic material in order to modify or manipulate the expression of either disease-causing or suppressor genes. Till date, a variety of gene-focused corrective strategies have been developed for the treatment of a wide range of genetic conditions, such as adenosine deaminase severe combined immunodeficiency (ADA-SCID), β-thalassemia, biallelic RPE65 mutation-associated retinal dystrophy, critical limb ischemia, head and neck squamous cell carcinoma, melanoma, peripheral artery disease and spinal muscular atrophy. It is worth mentioning that as of now, around 20 gene therapies have received approval; examples of recently USFDA approved gene therapies include (arranged in alphabetical order) Casgevy™ (developed by Vertex Pharmaceuticals, approved in 2024), Lenmeldy™ (developed by Orchard Therapeutics, approved in 2024), Lyfgenia™ (developed by bluebird bio, approved in 2023), Elevidys® (developed by Sarepta Therapeutics, approved in 2023), Roctavian® (developed by BioMarin Pharmaceutical, approved in 2023) and Vyjuvek® (developed by Krystal Biotech, approved in 2023). Considering that such therapies are designed to address the root cause (at the genetic level) of a disease, a number of contemporary drug / therapy development initiatives are focused on gene correction and genome editing-based therapeutic interventions. Further, the growing need for treatment options that can cure a clinical condition, as opposed to those intended for treatment of disease-related symptoms, has created a demand for more effective gene manipulation approaches.
Types of gene therapies
Gene augmentation therapy: In this type of therapy, a DNA segment representing the functional copy of a gene is inserted into cells (or tissues) that either lack or have dysfunctional copies of the same gene. Such an alteration usually results in restoration of normal function of the target cell / cell population.
Gene inhibition therapy: In this type of therapy, a DNA segment that is capable of either inhibiting the expression of a gene, or interfering with the activity of another gene, is introduced into a target cell / cell population.
Gene replacement therapy: In this type of therapy, a defective gene within a cell is replaced with a therapeutic gene by using an appropriate delivery vehicle (vector).
The future of gene therapy market- In recent years, gene therapy has been demonstrated to be a promising solution for patients suffering from severe inherited disorders. These therapies have shown remarkable outcomes in enhancing the life expectancy of patients suffering from severe conditions, such as AIDS, cancer, cystic fibrosis and diabetes. Further, with the rise in the RD activity in this domain along with advancements in gene editing technologies, an increasing number of novel gene therapies are likely to be commercialized in the coming years. It is worth highlighting that, according to Robert M. Califf, the former commissioner of the USFDA, more than ten gene therapies are anticipated to receive approval annually, by 2025.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Gene Therapy Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/gene-therapies-market/268.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
